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Abstract
BORIS (CTCFL) is the only known paralog of the versatile regulatory protein CTCF, a multifunctional DNA binding protein
that mediates distinct gene regulatory functions involved in cell growth, differentiation, and apoptosis. Unlike CTCF, the
expression of BORIS is normally restricted to specific cells in testes (the only cells where CTCF is not expressed), where it may
play a role in reprogramming the methylation pattern of male germ line DNA. Frequent amplification of the 20q13.2 region,
which contains the BORIS gene, and expression of BORIS transcripts in diverse human tumors and cell lines have led to the
hypothesis that aberrant expression of BORIS may play a role in tumorigenesis by interfering with CTCF functions. However,
recent studies using more quantitative methods indicate low frequency of BORIS expression in melanoma, ovarian, prostate,
and bladder carcinomas. To investigate the relationship between chromosome 20q13 amplification and BORIS mRNA levels
within breast cancer cell lines and tissues, we developed a quantitative RT-PCR assay to measure the levels of BORIS mRNA.
Endpoint RT-PCR assays were also used to investigate the possible expression of alternatively spliced variants. Using
multiple primer sets and controls, we found that neither mature BORIS transcripts nor spliced variants are commonly
expressed at detectable levels in malignant breast cells or tissues, although endogenous BORIS transcripts can be induced in
MCF-7 cells following 5-aza-29-deoxycytidine treatment. In conclusion, in most breast cancer cells, endogenous BORIS is
unlikely to be expressed at sufficient levels to interfere with CTCF functions. Thus it is improbable that aberrant BORIS
expression plays a role in most human breast cancers.
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Introduction
BORIS, first described as ‘‘Brother Of the Regulator of
Imprinted Sites,’’ or CTCF-like protein (CTCFL; NM_080618),
is the sole known paralog of CTCF (CCCTC-binding factor;
NM_006565) - a multifunctional DNA binding protein that uses
different sets of zinc fingers to mediate distinct functions in
regulation of gene expression. These functions include context-
dependent promoter repression or activation, creation of modular
hormone-responsive gene silencers, and formation of enhancer
blocking elements (insulators) (reviewed in [1–3]). Recent evidence
indicates that CTCF is involved in the global organization of
chromatin, and ‘‘may be a heritable component of an epigenetic
system regulating the interplay between DNA methylation, higher-
order chromatin structure, and lineage-specific gene expression’’
[3]. Unlike CTCF, the expression of BORIS is normally restricted
to specific cells in testes (the only cells where CTCF is not
expressed), where it may play a role in reprogramming the
methylation pattern of male germ line DNA [4].
The genomic organizations of the BORIS and CTCF genes, which
are located on chromosomes 20q13.2 and 16q22.1 respectively,
suggest that the two genes evolved from a gene duplication event
during vertebrate evolution [5]. The amino acid sequences
composing the two proteins’ eleven zinc finger motifs are nearly
identical, but the sequences at the amino- and carboxy- terminal
ends diverge markedly. This likely provides the proteins with similar
DNA binding specificities/affinities, yet distinct protein functions
[4]. In fact, Sun and colleagues have recently demonstrated, using a
DNA methylase-deficient cell model, that competition between
BORIS and CTCF is a possibility when both proteins are present in
equal amounts [6], a situationthat mayoccurincertain cancercells.
Aberrant expression of BORIS has been proposed to play a role in
tumorigenesis [7]. The 20q13.2 region where the BORIS gene is
located is commonly amplified in significant percentages of malignan-
cies in a variety of organs, and may harbor one or more oncogenes [8–
11]. Aberrantly expressed BORIS transcripts have also been reportedly
detected in diverse human tumors and tumor-derived cell lines,
including nearly all those derived from breast tissues [12–21]. Other
reports indicate BORIS contributes to the promoter-specific demeth-
ylation and derepression of several cancer-testis (CT; a class of genes
expressed normally in the testis, but activated in a wide range of tumor
types) genes [15,19],although BORIS expression byitself appears to be
insufficient for the induction of CT gene expression [22].
Despite its relationship to CTCF and its location within a
commonly amplified genomic region, recent findings in melano-
ma, ovarian, prostate, and bladder carcinomas [14,20,22] appear
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9738to controvert a broad tumorigenic role for BORIS. These studies
found that BORIS transcript expression was not as frequent in
primary melanomas (27%) [14,20,22] as originally estimated for
melanoma cell lines (90%) [14,20,22], and when measured
quantitatively, levels in tumors were not statistically different from
those in normal prostate, bladder, and ovarian tissues [14,20,22].
While initiating a study to investigate the molecular mechanism(s)
leading to the aberrant BORIS expression in breast cancers, we
have obtained similar discordant results regarding the expression
of BORIS. Using sensitive RT-PCR-based assays, employing
multiple primer sets, we find that neither mature BORIS
transcripts, nor spliced variants, are commonly expressed in
malignant breast cells. Thus it is unlikely that aberrant BORIS
expression plays a role in most human breast cancers.
Results
Nearly all breast cancer cell lines and tumors lack
detectable levels of BORIS mRNA
To investigate the relationship between chromosome 20q13
amplification and BORIS mRNA levels, we developed a quanti-
tative RT-PCR assay (exons 10–11, Figure 1) to measure the levels
of BORIS mRNA within breast cell lines having either normal or
amplified 20q13 DNA regions [23]. Sensitivity and amplification
efficiencies of the BORIS, CTCF, and TBP PCR reactions were
determined by amplifying dilutions of plasmids containing the
corresponding coding sequences (Table 1). The BORIS qRT-PCR
assay remained linear down to 2.86 attograms (2.86
218 g) of
plasmid DNA, equivalent to 24 copies of BORIS. Using the same
assay, BORIS transcript levels were undetectable in control BJ
fibroblasts; but in BJ fibroblasts transduced with CMV-HA-BORIS
adenovirus, were over 32,000 times greater than those in testis
(Table 1). Altogether, the results of these individual assays and
controls established the specificity, sensitivity, and large dynamic
range of the BORIS qRT-PCR assay.
Using this assay, we found evidence of BORIS expression in one
breast cancer-derived cell line, MDA-MB-436, at a level (0.033%
TBP) near the detection limit of 40 cycles (Figure 2A). A 24-fold
higher level of BORIS (0.809% TBP) was detected, however, in the
melanoma-derived MDA-MB-435 cell line. No evidence of BORIS
expression was found in any of the remaining breast cell lines.
Notably, neither MDA-MB-436 nor MDA-MB-435 exhibit 20q13
amplification (Table 1). Testis RNA was used as both a positive
control and reference of physiological levels of BORIS in all
experiments, and BORIS mRNA levels in testis were 272-fold
higher than levels in the MDA-MB-436 cells. The successful
amplification in all samples of TBP transcripts, used as internal
controls, confirmed both the integrity and successful reverse
transcription of the RNA (Table 1).
In addition to RT-PCR assays, we attempted to detect BORIS
protein by immunoblot analyses; however, all of the commercially
available antibodies that we tested were unable to detect BORIS
protein in MCF-7, MDA-MB-231, or MDA-MB-435 cell lines
infected with adenoviral BORIS expression vectors (data not
shown). Virally mediated BORIS mRNA expression was confirmed
in all three infected cell lines (7.1, 5.1, and 1.1% of the level of TBP
transcripts, respectively).
To investigate the prevalence and levels of BORIS expression
within breast tumors, samples of eight unrelated tissue specimens
were analyzed by qRT-PCR. All tumors were high grade (grade
III), invasive ductal carcinomas. BORIS transcripts were not
detected in any breast tumor samples (Table 1). In addition, two
non-malignant breast samples were also analyzed, and did not
express detectable levels of BORIS transcripts (Table 1).
An alternatively spliced variant of BORIS, missing exon 7,
is present in testis, but is absent in breast cancer cell lines
and tumors
To investigate the possibility that alternatively spliced forms of
BORIS, undetectable by the above qRT-PCR assay, were being
expressed in breast cell lines and tissues, we developed three
endpoint RT-PCR assays (Figure 1). The primers were designed to
detect all published BORIS transcripts, including those generated
Figure 1. BORIS mRNA and PCR design. The eleven exons of BORIS mRNA (ENSEMBL# ENST00000243914, CTCFL), and their corresponding sizes
(base pairs) are depicted as green arrows. The ATG start codon, area encoding the eleven zinc fingers (red arrows), and TGA stop codon are marked
for reference. The areas and sizes of the real-time PCR amplicon (10-11; bright-green box), and end-point PCR amplicons (2–6, 6–10, 2–11; blue boxes)
used to detect alternatively spliced variants, are indicated.
doi:10.1371/journal.pone.0009738.g001
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and the above-described controls, we found, in agreement with the
qRT-PCR data, that BORIS transcripts were detectable in MDA-
MB-435, testis, and BORIS-transduced fibroblasts. BORIS expres-
sion was not detectable in any of the remaining breast cell lines or
tissues (Table 1). A splice variant was present, however, in testis, as
indicated by two bands in both the Exon 2/11 (data not shown)
and Exon 6/10 PCR reactions (Figure 3); these two variants were
roughly equal in abundance. Variants were not detected using the
Exon 2/6 primers (Figure 3). The Exon 6/10 products were
isolated from agarose, cloned into the pGEMH T-Easy T/A vector
(Promega, Madison, WI), and analyzed by DNA sequencing. The
sequence of the larger product corresponded to the expected full-
length BORIS sequence located between the assay’s PCR primers.
Table 1. Detection of BORIS mRNA in breast cell lines, primary tumors, and controls.
Gene BORIS BORIS BORIS BORIS TBP
Exons (2–11) (2–6) (6–10) (10–11)
Data Type PCR band PCR band PCR band Ct value Ct value BORIS (%TBP)
Category Sample
Cell Lines MDA-MB-453 NP --ND 26.9 0
MDA-MB-231 ---ND 25.72 0
MCF-10A NP --ND 26.52 0
T47D NP --ND 26.79 0
MCF-12A NP --ND 26.76 0
MDA-MB-436 NP --37.71 26.17 0.033
MCF-7* - --ND 25.82 0
SUM185PE* NP --ND 26.91 0
UACC812* NP --ND 26.67 0
AU565* NP --ND 26.94 0
BT474* NP --ND 26.38 0
SKBR3* NP --ND 28.5 0
MDA-MB-435{ NP + + 35.11 28.16 0.809
Breast
Tumors T686 NP --ND 28.59 0
T688 NP --ND 31.39 0
T689 NP --ND 28.99 0
T691 NP --ND 29.9 0
T693 NP --ND 28.1 0
T694 NP --ND 27.85 0
T695 NP --ND 29.78 0
T-Amb NP --ND 29.95 0
Normal Breast
Tissues N-Amb NP --ND 29.9 0
N697 NP --NP # 0
Controls Water ---ND ND 0
minus RT ---ND ND 0
genomic DNA ---ND ND 0
Testes + + + 27.35 24.03 9.151
BORIS plasmids (dilution
series)
+ + + 18.47-35.34 NA NA
BJ Fibroblasts NP --ND 24.07 0
BJ + Adeno-BORIS NP + + 13.09 24.62 2.96610
5
Three endpoint RT-PCR assays, spanning different intron splice junctions, were designed to detect mature transcripts and alternatively spliced variants of BORIS mRNA
(2–11, 2–6, 6–10; Figure 1). These RT-PCR reactions were performed using RNA derived from cell lines, breast tumors, normal breast tissue, or several different positive
and negative controls (described in text). Cell lines with evidence of 20q13.2 amplification [23] are indicated by an asterisk (*). The detection of BORIS mRNA using the
different end-point PCR assays is indicated by a ‘‘+’’, whereas the lack of a product is indicated by a ‘‘-’’. NP = not performed. A quantitative real-time RT-PCR (qRT-PCR)
assay, spanning intron 10 (10–11), was used to quantify BORIS mRNA levels. The median threshold cycle (Ct; the PCR cycle for which products are detected above
baseline), of triplicate reactions is reported for both BORIS (10–11) and TBP. BORIS mRNA was not detected (ND) in most cell lines and all tumors. Quantitative results
were normalized and are expressed as a percentage of TBP expression (% TBP). For the N697 sample, only TBP end-point PCR was performed and it was positive (#).
MDA-MB-435 is considered to be melanoma-derived ({).
doi:10.1371/journal.pone.0009738.t001
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found in the larger product, in accordance with its estimated size
determined from the agarose gel. The missing sequence was
identified to be the entire seventh exon of BORIS.
BORIS expression is detected in MCF-7 cells following 5-
aza-29-deoxycytidine treatment
Treatment of cells with the demethylating agent, 5-aza-29-
deoxycytidine (5-aza-dC), has been previously demonstrated to
result in transcriptional activation and elevated levels of BORIS
mRNA [14,15,19,20]. To determine if similar effects occur in
breast cells (as well as to test our assay’s ability to detect
endogenous BORIS transcripts), we evaluated BORIS mRNA
levels by qRT-PCR in MCF-7 cells following exposure to 10 mM
5-aza-dC (72 hr exposure, followed by 24 hrs in growth medium
without 5-aza-dC). This treatment of MCF-7 cells resulted in an
increase in BORIS transcripts from undetectable levels to levels
roughly equivalent to those in MDA-MB-435 melanoma cells
(1.02 vs. 0.81%TBP), about 10% of the levels present in testis
(Figure 4).
Figure 2. BORIS and CTCF mRNA levels in cell lines. Levels of (A) BORIS and (B) CTCF mRNA were measured by real time PCR in cell lines and
testis (provided as a physiological control), and are reported relative to the levels of internal reference transcript TBP. BORIS mRNA was detectable in
the breast cell line, MDAMB436, and in the melanoma-derived cell line, MDAMB435, but not in the remaining breast-derived cell lines. CTCF mRNA
levels were near or above the levels of TBP mRNA in all cell lines. Testis expressed the lowest CTCF level, near the level of BORIS in this sample (note
the differences in scale between the graphs).
doi:10.1371/journal.pone.0009738.g002
BORIS and Breast Cancers
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Aberrant BORIS expression is currently hypothesized to
contribute to tumorigenesis by competing with CTCF for DNA
binding sites. To evaluate the feasibility of this hypothesis, we
measured CTCF mRNA levels in the breast tumor-derived cell
lines (Figure 2B). CTCF transcripts were detected within all cell
lines (and the testis control). Levels of CTCF mRNA ranged from
75–581% of TBP levels in the cell lines. Notably, testis exhibited
the lowest level of CTCF transcripts, nearly equivalent to the level
of BORIS mRNA in this sample (23.3 vs. 9.2% of TBP).
Discussion
In the course of investigating the relationship between
chromosome 20q13 amplification and its effects on BORIS
expression, we have found only a single cell line among 12 breast
cancer cell lines and 8 tumors to express detectable levels of BORIS
mRNA. We therefore conclude that the presence of 20q13
amplification is insufficient to derepress BORIS transcription, and
that aberrant BORIS expression in breast cells is not a prevalent
factor facilitating or maintaining their malignant character.
These results were unexpected, given claims of BORIS expression in
a large number of tumors and its absence in associated somatic tissues
[7,19,21]. To investigate this discordance, we re-evaluated both the
specificity and sensitivity of our qRT-PCR assay using several controls.
Specificity has been demonstrated by cloning and sequencing PCR
products, by detecting BORIS transcripts in cells transduced with a
BORIS-encoding adenovirus, and by the lack of PCR products in all
negative controls (-RT, water, genomic DNA). Sensitivity of the assay
has been demonstrated by amplifying log dilutions of a BORIS-
containing plasmid. In addition, wew e r ea b l et os u c c e s s f u l l yd e t e c t
endogenous BORIS mRNA in testis, two (breast- and melanoma-
derived) cell lines, as well as in MCF-7 cells treated with 5-aza-dC.
Figure 3. Expression of an alternatively spliced variant of BORIS
in testis. BORIS specific primers, designed to amplify the region of
BORIS between exons 2–6 (lanes 1–3) and exons 6–10 (lanes 5–7), were
used to screen for possible alternatively spliced variants of BORIS. The
expected sizes of these two products, based on the published sequence
of mature BORIS mRNA, are 608 bp and 693 bp, respectively. These full-
length products were present when testis cDNA (lane 1 & 5) and a
plasmid containing a full length BORIS cDNA (lane 3 & 7) were used as
PCR templates. In testis, an additional band (543 bp) was also amplified
by the exon 6–10 PCR primers (lane 5). PCR products were not present
in the testis (-RT) negative control reactions (lanes 2 & 6).
doi:10.1371/journal.pone.0009738.g003
Figure 4. Endogenous BORIS mRNA expression is induced by 5-aza-29-deoxycytidine. BORIS mRNA levels in MCF-7 cells were determined
by qRT-PCR (as in Figure 2). Endogenous BORIS mRNA was detectable (1.02% TBP) only after treatment with the demethylating agent, 5-aza-29-
deoxycytidine (5-aza-dC) and at a level approximately one tenth of that in testis (1.02% vs. 10.47% TBP).
doi:10.1371/journal.pone.0009738.g004
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splice variants that, if expressed in place of full-length BORIS,
would lead to false-negative results. No such variants were
determined to be present in any of the breast tissues or cell lines.
However, a splice variant was detected in the testis, and it was
expressed at approximately the same level as the full-length BORIS
mRNA. This variant, which lacks exon 7 (encoding part of the
zinc finger region), may have an important function in the testis,
and its presence warrants further investigation.
Our results are inconsistent with those of Vatolin and
colleagues, who reportedly detected expression of BORIS by
endpoint RT-PCR in 7/8 breast cell lines and 11/12 breast
tumors using PCR primers that span exons 3–10 [19]. Five of
these eight cell lines are common to this study: T47D, MDA-MB-
231, MDA-MB-453, MCF-7, and MDA-MB-435. Notably, the
region amplified in our exon 6–10 PCR reactions was flanked by
the same reverse primer sequence used by Vatolin et al. [19].
Therefore, the results of these two assays should have correspond-
ed. Furthermore, we did not detect BORIS transcripts in any of the
eight primary breast tumors we investigated, all of which were
grade III tumors. Histopathological information was not provided
in the original publication by Vatolin et.al., precluding a
comparison of the tumor stage/grade in the two studies. In a
more recent publication, this group reported that both BORIS
mRNA and protein were detectable in multiple invasive breast
carcinomas, although again stage and grade were not specified
[7,19,21].
Overall, we did not detect BORIS mRNA in 6 of the 7 breast cell
lines determined to be positive by Vatolin et.al. [19]. However, in
accordance with their results, we did demonstrate BORIS mRNA
expression in MDA-MB-435 cells and lack of expression in MCF-7
cells. The later report from this group [21] that MCF-7 cells express
BORIS protein is in apparent conflict with this result. Our finding
that 5-aza-dC treatment resulted in the activation of BORIS
expression in MCF-7 cells is also consistent with previous findings.
Of the two cell lines that we did find to be BORIS-positive, MDA-
MB-435 cells expressed the highest levels of BORIS transcripts.
However, although previously believed to be a breast cell line,
MDA-MB-435iscurrentlyregardedasaderivativeofthemalignant
melanoma cell line M14 [25,26]. This is notable due to the frequent
expression of CT genes in melanomas; e.g., MAGEA1 (reviewed in
[27]). Thus, the melanoma origin of MDA-MB-435 may explain
why BORIS expression was found in this cell line.
We have determined and described both the specificity and
sensitivity of our assays, and cannot account for these discrepant
results other than to suggest that the levels described by Vatolin
et.al. may have been lower than our threshold of detection. It is
possible that the high number of PCR cycles used by Vatolin et al.
(40–45 cycles) led to the detection of faint BORIS expression,
possibly from subpopulations of cells. Based on their endpoint RT-
PCR data, however, BORIS and CTCF transcripts appeared to be
expressed at roughly equivalent levels in the breast cell lines. This
contrasts with our qRT-PCR data in which we saw robust CTCF
expression but undetectable BORIS levels in most cell lines and
tissues. Although one other study has reported that BORIS protein
is expressed in MDA-MB-231 cells [7,19,21], we were unable to
detect BORIS mRNA in this cell line. In addition, using the same
commercial antibody, we were unable to confirm the expression of
BORIS protein in MDA-MB-231 cells. We cannot account for
these discrepant findings, other than to suggest that variations in
the cell line might be responsible. Nevertheless, our general
conclusion is supported by other studies that have used serial
analysis of gene expression (SAGE) to investigate aberrant gene
expression in breast tumors and cell lines [28,29]. These SAGE
studies did not report the expression of BORIS mRNA in the
samples analyzed. Notably, the study by Yao et al. [28] was
specifically designed to identify differentially expressed genes
encoded within commonly amplified chromosomal regions,
including the 20q13 region where the BORIS gene is located.
Aberrant BORIS expression has been proposed to facilitate cell
transformation by competing for CTCF binding sites, leading to
disruption of insulator boundaries and abnormal gene expression
[7]. For a competition model to be feasible in breast cancer, levels
of BORIS and CTCF mRNA and/or protein would have to be
comparable. We found however, that while CTCF mRNA was
quite abundant in breast cells, BORIS mRNA was generally below
our detection limit. Even in the MDA-MB-468 breast cell line, in
which BORIS transcripts were detectable, levels of CTCF mRNA
were, on average, at least 9000-fold higher than those of BORIS
mRNA. At these disparate levels, it is unlikely that differences in
protein stability would make sufficient BORIS protein available to
compete with CTCF at DNA binding sites. Thus, aberrant
BORIS expression is unlikely to compete with CTCF, even in the
rare breast cancer cell line in which it is expressed.
Materials and Methods
Tissue Samples
Frozen breast tissue specimens (seven malignant, and one
reduction mammoplasty sample) were provided by the Cooper-
ative Human Tissue Network. The tumor specimens were grade
III (Scarf-Bloom-Richardson) invasive ductal carcinomas. Individ-
ual samples of RNA isolated from non-malignant and malignant
breast, as well as testis, were purchased from Ambion (Austin,
TX).
Cell Culture
Normal BJ fibroblasts and the breast cancer-derived cell lines:
MDA-MB-453; MDA-MB-231; T47D; MDA-MB-436; MCF-7;
UACC-812; AU-565; BT474; and SK-BR-3; the non-malignant
derived cell lines: MCF-10A and MCF-12A; as well as the MDA-
MB-435 cell line, which is currently regarded to be a derivative of
the M14 malignant melanoma cell line (and will be referred to as
such herein) [25,26], were obtained from the American Type
Culture Collection. Another breast cancer cell line, SUM185PE,
was provided by Dr. Joe Gray (LBNL). Cells were propagated and
subcultured using conditions indicated by the supplier.
BORIS Adenovirus
To create the recombinant adenovirus, a 3483 bp NheI/NotI
DNA fragment, containing the BORIS coding region, was
subcloned from pBIG2i-HA BORIS (generously provided by V.
Lobanenkov, NIH) [15]. This fragment was ligated into an NheI/
Not I linearized pShuttle vector (Adeno-X
TM Expression System,
Clontech). Generation of recombinant adenovirus and virus
particles were completed using the manufacturer’s protocol. This
adenovirus contains the coding sequence of HA-tagged BORIS,
verified by DNA sequencing, under control of the CMV promoter.
Adenovirus titers were determined by immunocytochemical
detection of the adenovirus hexon protein in infected HEK293
cells (Adeno-X
TM Rapid Titer, Clontech). This virus was used to
infect BJ fibroblasts using 10 infection-forming units per cell.
Functional activity of the BORIS adenovirus was confirmed by
qRT-PCR using RNA isolated from transduced cells.
RNA Isolation and Reverse Transcription
Total RNA was isolated using silica-based spin-column
extraction kits (RNeasy mini kit, Qiagen) using the manufacturer’s
BORIS and Breast Cancers
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(Ambion) to reduce contaminating DNA. RNA integrity was
evaluated by agarose gel electrophoresis using Gel Star (Cambrex)
nucleic acid gel stain. Complimentary DNA (cDNA) was
synthesized from 2 mg of total RNA by random-decamer primed
reverse transcription using the Retroscript reverse transcription kit
(Ambion) and the manufacturer’s standard protocol. Negative
(-RT) controls contained RNase-free water substituted for reverse
transcriptase.
Quantitative Real-Time PCR
BORIS and CTCF mRNA levels were measured in breast tissue
specimens and cell lines using the PlatinumH Quantitative PCR
Supermix (Invitrogen). The sequences of forward primers, reverse
primers, and Taqman probes for the systems are described in
Table 2. Both transcripts were amplified in parallel, along with a
stably expressed reference gene, TBP (TATA box binding protein;
NM_003194), in triplicate reactions, from equal amounts of cDNA
(1 ml of the reverse transcription reaction). The qRT-PCR BORIS
primers amplify a 205 base pair (bp) sequence spanning the splice
junction between exons 10 and 11, flanking a 4734 bp intron.
CTCF mRNA levels were measured by SYBR Green qRT-PCR
(SYBR Greener
TM, Invitrogen), using the same conditions and
controls described for the BORIS qRT-PCR assay. The CTCF
primers amplify a 135 bp sequence element and flank a 3818 bp
intron. The final concentrations were 300 nM of each forward and
reverse primer, and 100 nM of probe, when used. PCR
amplification was performed using the Biorad MyiQ Single-Color
Real-Time PCR Detection System using the following standard
amplification protocol: 50uC62 min, 95uC62 min, 40 cycles:
95uC615 sec, 60uC660 sec. Testis cDNA and plasmid DNA
containing the BORIS coding sequence were used as positive
controls, as was cDNA from fibroblasts transduced with the
BORIS-containing adenovirus. Water and –RT reactions were
both used as negative controls to detect possible amplification from
contaminating DNA. The identities of the PCR products were
confirmed by gel analyses and DNA sequencing. Amplification
efficiencies, determined by amplifying log dilutions of plasmids
containing the corresponding coding sequences, were determined
to be near 100%. Relative levels of BORIS and CTCF transcripts
were calculated using the delta Ct method and normalized to those
of the TBP reference transcript using the formula: %TBP =
2
2(Ct (BORIS)2Ct (TBP))6100%. Standard deviations of triplicate
reactions were used to propagate error using the square root of the
sum of squares method.
Splice Variant Screening by Conventional PCR
To detect the possible presence of alternatively spliced BORIS
transcripts, three end-point PCR reactions were developed
(Figure 1). Primer pairs were designed to amplify regions of
BORIS mRNA between: 1) exons 2 and 11, 2) exons 2–6, and 3)
exons 6–10. Reactions were performed using SYBRH GreenER
PCR reagent (Invitrogen) and the Biorad PCR Detection System.
The amplification parameters for these PCR assays were: 1)
50uC62 min, 95uC68.5 min, followed by 45 cycles 95uC630 sec,
58uC630 sec, 72u62.5 min; 2) and 3) 50uC62 min, 95uC68.5 min,
followed by 45 cycles 95uC615 sec, 60uC630 sec, 72u61.5 min.
Reaction products were analyzed as described above.
Immunoblot Analysis
BORIS protein levels were analyzed in MCF-7, MDA-MB-231,
and MDA-MB-435 cell lines. To serve as positive controls, each of
these cell lines was infected with the BORIS adenovirus, and the
resulting expression of BORIS mRNA was confirmed by qRT-
PCR. Parallel cell cultures were lysed in RIPA buffer (50 mM
TrisNHCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% Na Deoxy-
cholate, 0.1% SDS) containing protease (Protease Inhibitor
Cocktail Set III EDTA-free, Calbiochem) and phosphatase
(Phosphatase Inhibitor Cocktail Set II, Calbiochem) inhibitors,
both diluted 1:100. The lysates were incubated on ice for 15
minutes, then centrifuged 24,0006g for 30 min at 4uC. Twenty-
five micrograms of each lysate were loaded per well onto 4–12%
gradient polyacrylamide gels (NuSep). After electrophoresis, the
proteins were transferred to nitrocellulose, and probed with
antibodies using standard conditions. Three anti-Boris antibodies
were tested: Abcam (Ab18337, lots 123956 and 469726, 1:2500
dilution), Rockland (600-401-907, lot 21606, 1:1000 dilution), and
Sigma (HPA001472, lot A08951, 4 ug/ml final concentration).
The blots were probed with anti-b-actin antibodies (Sigma,
A1978, lot 118K4827) to control for loading differences. Signals
were imaged using an Odyssey infrared imaging system (Licor
Biosciences).
Acknowledgments
We thank Dr. V. Lobanenkov for valuable discussions and reagents.
Author Contributions
Conceived and designed the experiments: WCH PY. Performed the
experiments: WCH AB RM. Analyzed the data: WCH AB RM PY.
Contributed reagents/materials/analysis tools: WCH. Wrote the paper:
WCH AB RM PY.
References
1. Ohlsson R, Renkawitz R, Lobanenkov V (2001) CTCF is a uniquely versatile
transcriptionregulatorlinkedtoepigeneticsanddisease.TrendsGenet17:520–527.
2. Filippova GN (2008) Genetics and epigenetics of the multifunctional protein
CTCF. Curr Top Dev Biol 80: 337–360.
Table 2. Quantitative RT-PCR primer and probe sequences.
BORIS, Exon 10/11
(qPCR)
For 59- ACCTGCACAGACATTCGGAGAAGT
Rev 59- AACTGTTCTCCCTTCGTGGTGGAA
Probe 59- 6FAM-TTCCCTTTCCTGAAGCAGCCGACTTTGC-
BHQ
BORIS, Exon 2/11 For 59- TGTGCAGAGAGAAAGACCATCGGA
Rev 59- GCAGTGAACATGCAACCTGACTCT
BORIS, Exon 2/6 For 59- TGGTGGCCAGTGAAGACAGTAAGT
Rev 59- GGATCGGACATGGCGCTTCAATTT
BORIS, Exon 6/10 For 59- CTTTCAGTGTTGCCAGTGCAGCTA
Rev 59- TTCTGACCCTTTGTGGCTTCCTTC
CTCF For 59- TCGTCGTTACAAACACACCCACGA
Rev 59- CTGCACAAACTGCACTGAAACGGA
TBP For 59- CACGAACCACGGCACTGATT
Rev 59- TTTTCTTGCTGCCAGTCTGGAC
Probe 59- 6FAM-TGTGCACAGGAGCCAAGAGTGAAGA-
BHQ
doi:10.1371/journal.pone.0009738.t002
BORIS and Breast Cancers
PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e97383. Phillips JE, Corces VG (2009) CTCF: master weaver of the genome. Cell 137:
1194–1211.
4. Loukinov DI, Pugacheva E, Vatolin S, Pack SD, Moon H, et al. (2002) BORIS,
a novel male germ-line-specific protein associated with epigenetic reprogram-
ming events, shares the same 11-zinc-finger domain with CTCF, the insulator
protein involved in reading imprinting marks in the soma. Proc Natl Acad
Sci U S A 99: 6806–6811.
5. Hore TA, Deakin JE, Marshall Graves JA (2008) The evolution of epigenetic
regulators CTCF and BORIS/CTCFL in amniotes. PLoS Genet 4: e1000169.
6. Sun L, Huang L, Nguyen P, Bisht KS, Bar-Sela G, et al. (2008) DNA
methyltransferase 1 and 3B activate BAG-1 expression via recruitment of
CTCFL/BORIS and modulation of promoter histone methylation. Cancer Res
68: 2726–2735.
7. Klenova EM, Morse HC, 3rd, Ohlsson R, Lobanenkov VV (2002) The novel
BORIS + CTCF gene family is uniquely involved in the epigenetics of normal
biology and cancer. Semin Cancer Biol 12: 399–414.
8. Tanner MM, Tirkkonen M, Kallioniemi A, Holli K, Collins C, et al. (1995)
Amplification of chromosomal region 20q13 in invasive breast cancer:
prognostic implications. Clin Cancer Res 1: 1455–1461.
9. Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, et al. (1994)
Detection and mapping of amplified DNA sequences in breast cancer by
comparative genomic hybridization. Proc Natl Acad Sci U S A 91: 2156–2160.
10. Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, et al. (2000)
Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer.
Clin Cancer Res 6: 1833–1839.
11. Mahlamaki EH, Barlund M, Tanner M, Gorunova L, Hoglund M, et al. (2002)
Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic
cancer. Genes Chromosomes Cancer 35: 353–358.
12. D’Arcy V, Abdullaev ZK, Pore N, Docquier F, Torrano V, et al. (2006) The
potential of BORIS detected in the leukocytes of breast cancer patients as an
early marker of tumorigenesis. Clin Cancer Res 12: 5978–5986.
13. Dougherty CJ, Ichim TE, Liu L, Reznik G, Min WP, et al. (2008) Selective
apoptosis of breast cancer cells by siRNA targeting of BORIS. Biochem Biophys
Res Commun 370: 109–112.
14. Hoffmann MJ, Muller M, Engers R, Schulz WA (2006) Epigenetic control of
CTCFL/BORIS and OCT4 expression in urogenital malignancies. Biochem
Pharmacol 72: 1577–1588.
15. Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, et al. (2005) Reciprocal
binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with
derepression of this cancer-testis gene in lung cancer cells. Cancer Res 65:
7763–7774.
16. Looijenga LH, Hersmus R, Gillis AJ, Pfundt R, Stoop HJ, et al. (2006) Genomic
and expression profiling of human spermatocytic seminomas: primary
spermatocyte as tumorigenic precursor and DMRT1 as candidate chromosome
9 gene. Cancer Res 66: 290–302.
17. Risinger JI, Chandramouli GV, Maxwell GL, Custer M, Pack S, et al. (2007)
Global expression analysis of cancer/testis genes in uterine cancers reveals a high
incidence of BORIS expression. Clin Cancer Res 13: 1713–1719.
18. Ulaner GA, Vu TH, Li T, Hu JF, Yao XM, et al. (2003) Loss of imprinting of
IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation
changes of a CTCF-binding site. Hum Mol Genet 12: 535–549.
19. Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, et al. (2005)
Conditional expression of the CTCF-paralogous transcriptional factor BORIS in
normal cells results in demethylation and derepression of MAGE-A1 and
reactivation of other cancer-testis genes. Cancer Res 65: 7751–7762.
20. Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, et al. (2007) DNA
methylation-dependent regulation of BORIS/CTCFL expression in ovarian
cancer. Cancer Immun 7: 21.
21. D’Arcy V, Pore N, Docquier F, Abdullaev ZK, Chernukhin I, et al. (2008)
BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed
in breast tumours. Br J Cancer 98: 571–579.
22. Kholmanskikh O, Loriot A, Brasseur F, De Plaen E, De Smet C (2008)
Expression of BORIS in melanoma: lack of association with MAGE-A1
activation. Int J Cancer 122: 777–784.
23. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of
breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10: 515–527.
24. Renaud S, Pugacheva EM, Delgado MD, Braunschweig R, Abdullaev Z, et al.
(2007) Expression of the CTCF-paralogous cancer-testis gene, brother of the
regulator of imprinted sites (BORIS), is regulated by three alternative promoters
modulated by CpG methylation and by CTCF and p53 transcription factors.
Nucleic Acids Res 35: 7372–7388.
25. Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD (2007) MDA-MB-
435 cells are derived from M14 Melanoma cells–a loss for breast cancer, but a
boon for melanoma research. Breast Cancer Res Treat 104: 13–19.
26. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, et al. (2000) Systematic
variation in gene expression patterns in human cancer cell lines. Nat Genet 24:
227–235.
27. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis
antigens, gametogenesis and cancer. Nat Rev Cancer 5: 615–625.
28. Yao J, Weremowicz S, Feng B, Gentleman RC, Marks JR, et al. (2006)
Combined cDNA array comparative genomic hybridization and serial analysis
of gene expression analysis of breast tumor progression. Cancer Res 66:
4065–4078.
29. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, et al. (2004)
Molecular characterization of the tumor microenvironment in breast cancer.
Cancer Cell 6: 17–32.
BORIS and Breast Cancers
PLoS ONE | www.plosone.org 8 March 2010 | Volume 5 | Issue 3 | e9738